National Kidney Foundation

CYNTHIA DELGADO AND NEIL POWE NAMED TO TIME100 HEALTH LIST FOR FIGHTING KIDNEY TRANSPLANT BIAS

Retrieved on: 
星期四, 五月 2, 2024
Task force, FASN, National Kidney Foundation, Filtration, Risk, Kidney failure, Health, Kidney, Cystatin C, GFR, Black, TIME, Creatinine, CKD, Organ, Patient, American Society of Nephrology, Society, MPH, Kidney transplantation, ASN, MBA, NKF, Chronic kidney disease, Pioneer, Global health, Nursing

The magazine recognized Cynthia Delgado, MD, FASN and Neil Powe, MD, MPH, MBA for their efforts to correct racial bias in the algorithm used to diagnose kidney diseases, an algorithm that often determines access to a kidney transplant.

Key Points: 
  • The magazine recognized Cynthia Delgado, MD, FASN and Neil Powe, MD, MPH, MBA for their efforts to correct racial bias in the algorithm used to diagnose kidney diseases, an algorithm that often determines access to a kidney transplant.
  • TIME included NKF/ASN Task Force co-chairs in its first-ever list of the 100 most influential people in global health.
  • Under the updated, race-free algorithm, some Black patients recently received modified times on the wait list for a kidney transplant.
  • The TIME100 Health List recognizes the world's most influential individuals in health across five categories: Innovators, Titans, Pioneers, Leaders, and Catalysts.

HEALWELL Subsidiaries, Khure Health & Pentavere Research Group, to Participate and Present at Upcoming Globally Recognized Medical Conferences

Retrieved on: 
星期三, 四月 17, 2024
Public, CPD, Real, Nephrology, Ophthalmology, AIDX, National Kidney Foundation, AI, Research, Health, AMIA, TSX, American Head, Conference, Artificial intelligence, Chronic kidney disease, Guideline, QC, Health information management, Oropharyngeal cancer, Patient, Faculty, Otorhinolaryngology, American Medical Informatics Association, NKF, Entertainment center, Knowledge

Pentavere will be presenting at the following medical conferences:

Key Points: 
  • Pentavere will be presenting at the following medical conferences:
    Canadian Retina Society Annual Meeting on May 3-5, 2024 in Montreal, QC.
  • American Medical Informatics Association (AMIA) Clinical Informatics Conference on May 21-23, 2024 in Minneapolis, MN.
  • Presenting Research: Using Artificial Intelligence to automate the extraction of staging criteria from the electronic health records of oropharyngeal cancer patients.
  • Thought leaders driving the future of healthcare delivery will explore practice-ready solutions to enhance patient experiences, reduce costs, and improve public health.

Makana™ Issued Patent in South Korea for Its Genetically-Modified TKO Pig for Use in Xenotransplantation

Retrieved on: 
星期三, 五月 1, 2024
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, University, Genetics, National Kidney Foundation, Food, Kidney failure, Makana, Immunosuppression, Doctor of Philosophy, Jackson Memorial Hospital, Medicine, FACS, Organ transplantation, Patent, Massachusetts General Hospital, TKO, Patient, MTI, Kidney, Maryland School, Immune system, Clinical trial, Therapy, Quality of life, Pelvic floor dysfunction, Pharmaceutical industry

Makana™ Therapeutics, a global leader in the field of xenotransplantation, was granted an important patent in South Korea that will catalyze xenotransplantation efforts in that country, the company announced today.

Key Points: 
  • Makana™ Therapeutics, a global leader in the field of xenotransplantation, was granted an important patent in South Korea that will catalyze xenotransplantation efforts in that country, the company announced today.
  • The South Korean patent was granted on Makana’s Triple Knockout pig, or “TKO,” which is a combination of three xenoantigen gene knockouts in the pig that effectively camouflage the cross-species grafts from the human recipient’s immune system.
  • Platt added, “The Triple Knockout Pig has fundamentally changed the field and has moved xenotransplantation closer to becoming a clinically available reality.
  • “The TKO pig is widely seen as the preferred genetic profile that will enter clinical trials,” Platt said.

Toku Inc. Secures FDA Breakthrough Designation for Technology that Identifies Chronic Kidney Disease Risk Through the Eye

Retrieved on: 
星期二, 四月 30, 2024
Software, Research, Optical, Medical Devices, Technology, Artificial Intelligence, Science, Biotechnology, FDA, Other Science, Health, Diabetes, Health policy, Nephrology, Kidney disease, Patient, Disorder, Population health, System, National Kidney Foundation, Risk, AI, Food, Kidney failure, Death, Health care, Breakthrough, Disease, CKD, Retina, Eye, Developed country, Kidney transplantation, Dialysis, Microangiopathy, Medicare, Multimedia, Chronic kidney disease, Overalls, Pharmaceutical industry

Toku, Inc., a commercial medical device company specializing in imaging technology and AI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its MyKidneyAI technology.

Key Points: 
  • Toku, Inc., a commercial medical device company specializing in imaging technology and AI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its MyKidneyAI technology.
  • MyKidneyAI uses AI to analyze retinal images collected at routine eye exams to detect elevated chronic kidney disease (CKD) risk in people with diabetes.
  • Toku developed MyKidneyAI to help identify individuals with diabetes who have elevated CKD risk via a simple eye exam available in eye care or primary care settings.
  • FDA's Breakthrough designation expedites the review process, shortening the time until technology reaches patients if cleared by the FDA.

The National Kidney Foundation Urges Passage of New Home Dialysis Bill

Retrieved on: 
星期二, 四月 23, 2024
Education, Congress, Patient, National Kidney Foundation, Kidney, Transplant, Travel, Disability, Health, House, Employment, Kidney disease, Senate, Renal replacement therapy, Nursing, ESKD, Legislation, Dialysis, Earl Blumenauer, Crash, Quality of life, NKF

WASHINGTON, April 23, 2024 /PRNewswire/ -- The National Kidney Foundation is applauding a move by Congress to increase access to care and improve outcomes for some patients on dialysis. The Improving Access to Home Dialysis Act (HR-8075) was introduced today in the U.S. House of Representatives by Reps. Carol Miller (R-WV), Marilyn Strickland (D-WA), Earl Blumenauer (D-OR), and Mariannette Miller-Meeks (R-IA). A companion bill is expected to be introduced soon in the Senate.

Key Points: 
  • WASHINGTON, April 23, 2024 /PRNewswire/ -- The National Kidney Foundation is applauding a move by Congress to increase access to care and improve outcomes for some patients on dialysis.
  • Home dialysis is a form of renal (kidney) replacement therapy (aka, dialysis) that can be done at home by the patient alone or with the help of a care partner.
  • "Patients deserve to know about all options for dialysis so they can make an educated choice for themselves," said Kevin Longino, Chief Executive Officer of the National Kidney Foundation and a kidney transplant recipient.
  • "Policies like this make me increasingly optimistic that more kidney patients struggling with dialysis can have a chance to get some of their life back."

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
星期四, 三月 28, 2024
ODD, Research, Hyperphosphatemia, DGF, CRRT, ERA, Administration, Congress, Conference, OLC, CKD, Patient, AKI, National Kidney Foundation, Mitochondrion, NDA, Kidney transplantation, Insurance, Kidney disease, Critical care, Acute kidney injury, Clinical trial, Therapy, Drug development, Safety, Chronic kidney disease, Dialysis, LOS, Research and development, SAD, FDA, KATP, Food, Pharmaceutical industry

LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.

Key Points: 
  • LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.
  • Completed a private placement with new and existing healthcare institutional investors that generated $50 million in gross proceeds to Unicycive.
  • Cash Position: As of December 31, 2023, cash and cash equivalents totaled $9.7 million.
  • Subsequent to year end, in March 2024, Unicycive completed a private placement of preferred stock which generated $50 million in gross proceeds.

HHS Technology Group Introduces ConstellationAI to Power Healthcare Digital Asset Discovery with Artificial Intelligence

Retrieved on: 
星期二, 四月 2, 2024
Harness, COVID-19, National Kidney Foundation, Constellation, AI, HTG, Heart, Creativity, Federated, Cryptocurrency

FORT LAUDERDALE, Fla., April 2, 2024 /PRNewswire/ -- HHS Technology Group, LLC™ (HTG) announced today that it has introduced ConstellationAI, an artificial intelligence-driven healthcare digital asset marketplace that holds the potential to catalyze discovery, drive innovation, and unlock hidden value.

Key Points: 
  • FORT LAUDERDALE, Fla., April 2, 2024 /PRNewswire/ -- HHS Technology Group, LLC™ (HTG) announced today that it has introduced ConstellationAI , an artificial intelligence-driven healthcare digital asset marketplace that holds the potential to catalyze discovery, drive innovation, and unlock hidden value.
  • With ConstellationAI, users can discover and connect different digital assets leveraging an advanced studio for model development and federated asset discovery.
  • By seamlessly integrating state-of-the-art AI capabilities with a unique federated asset discovery methodology, we are delivering unparalleled efficiency, productivity, and results."
  • ConstellationAI leverages the power of HTG's revolutionary data platform, Discover your Data® (DyD®), alongside cutting-edge AI technology to help researchers unlock unparalleled insights and opportunities.

BLACK AMERICANS AT HIGHER RISK FOR KIDNEY FAILURE AS BLACK HEALTH MATTERS, NATIONAL KIDNEY FOUNDATION FIGHT FOR EQUITY DURING NATIONAL KIDNEY MONTH

Retrieved on: 
星期四, 三月 14, 2024
Health, BHM, NKF, Risk, Diabetes, Global health, Patient, National Kidney Foundation, EQUITY, ALL, Social media, Kidney failure, Kidney disease, Kidney, Chronic kidney disease, World Kidney Day, All, Pharmaceutical industry

NEW YORK, March 14, 2024 /PRNewswire/ -- Black Health Matters (BHM)– a leading nonprofit health advocacy organization that provides health and wellness information that is rooted in medical expertise to the Black community – is partnering with the National Kidney Foundation (NKF) to spread awareness about kidney equity during National Kidney Month. Observed in March each year, National Kidney Month aims to raise awareness about kidney health and chronic kidney disease. The month also includes World Kidney Day – a global health awareness day focusing on the importance of kidneys and the impact of kidney disease - which is observed March 14.

Key Points: 
  • Observed in March each year, National Kidney Month aims to raise awareness about kidney health and chronic kidney disease.
  • The month also includes World Kidney Day – a global health awareness day focusing on the importance of kidneys and the impact of kidney disease - which is observed March 14.
  • NKF continues to fight to get Kidney Equity for All - a commitment to make a difference in ALL kidney patients' lives!
  • "As an organization that spotlights health disparities and the importance of health in the Black community, kidney health has become a silent epidemic in our community," said Roslyn Young-Daniels, President, and Founder of Black Health Matters.

Panoramic Health Launches Scientific Advisory Board to Accelerate Innovation in Kidney Care

Retrieved on: 
星期四, 三月 7, 2024
Doctor of Philosophy, Person, Dialysis, Health, University, Acute kidney injury, Health policy, Kidney disease, Diagnosis, Literature, Belding, Michigan, ASN, Bangladesh Technical Education Board, Chronic kidney disease, National Kidney Foundation, NIH, Johns Hopkins, National Academy of Medicine, UNC, Partnership, American Kidney Fund, CKD, Kidney, Biomarker, Prognosis, MPH, Research, Division, Public policy, Population health, FDA, National academy, Entrepreneurship, Society, Patient, Physician, Pharmaceutical industry

TEMPE, Ariz., March 7, 2024 /PRNewswire/ -- Today, Panoramic Health, kidney care's leading integrated provider group, is proud to announce the establishment of its Scientific Advisory Board, a distinguished group of clinical leaders and research experts committed to advancing kidney care innovation. With a focus on uncovering and delivering cutting-edge treatments for patients with kidney disease, the advisory board will play a crucial role in guiding Panoramic Science, the company's clinical research division.

Key Points: 
  • TEMPE, Ariz., March 7, 2024 /PRNewswire/ -- Today, Panoramic Health, kidney care's leading integrated provider group, is proud to announce the establishment of its Scientific Advisory Board, a distinguished group of clinical leaders and research experts committed to advancing kidney care innovation.
  • "At Panoramic Health, we are dedicated to redefining the standard of kidney care through innovation and collaboration," said Dr. Rajiv Poduval, Co-Founder and Executive Chairman of Panoramic Health.
  • "Our Scientific Advisory Board brings together exceptional expertise that will drive our efforts to enhance patient care and transform the evolving landscape of kidney disease treatment.
  • Panoramic Health leadership team members serving on the advisory board include:
    The establishment of the Scientific Advisory Board underscores Panoramic Health's commitment to driving innovation and improving the lives of patients with kidney disease.

National Kidney Foundation Recognizes March as National Kidney Month

Retrieved on: 
星期四, 二月 29, 2024
African Americans, Chronic kidney disease, Hospital, National Kidney Foundation, ALL, Organ, MD, KDRI, NKF, Government, Risk, Federally Qualified Health Center, CKD, OPTN, Transplant, White, EGFR, Patient, Policy, Kidney disease, Priority, Kidney, Diagnosis, Mortality, Plague, FQHC, Kidney failure, Pharmaceutical industry

NEW YORK, Feb. 29, 2024 /PRNewswire/ -- As March approaches, the National Kidney Foundation (NKF) is gearing up to observe National Kidney Month, a crucial time dedicated to raising awareness about kidney health and chronic kidney disease (CKD). With World Kidney Day falling on Thursday, March 14th, this month holds particular significance in advocating for KIDNEY EQUITY FOR ALL™.

Key Points: 
  • NEW YORK, Feb. 29, 2024 /PRNewswire/ -- As March approaches, the National Kidney Foundation (NKF) is gearing up to observe National Kidney Month, a crucial time dedicated to raising awareness about kidney health and chronic kidney disease (CKD).
  • With World Kidney Day falling on Thursday, March 14th, this month holds particular significance in advocating for KIDNEY EQUITY FOR ALL™ .
  • "Despite this, they are exposed to inequities in kidney care including evaluation and obtaining a kidney transplant.
  • To mark National Kidney Month and World Kidney Day, NKF is highlighting several ways the organization is promoting kidney equity.